Field-proven COVID-19 Telemedicine Solution for Hospitals

Deployable Within 48 Hours: Launched by Datos Leveraging Accumulated Experience in Monitoring Coronavirus Symptoms, Israeli Telehealth Company Releases Solution to Avoid Low-risk Patients Overwhelming Hospitals

As COVID-19 continues to spread, hospitals are expecting a surge in visitors to clinics and emergency rooms, which would result in a challenging additional burden on an already overstretched medical system.

Datos’s solution, easily implemented within 48 hours, is specifically designed to support hospitals across the world to mitigate such a situation by helping to keep suspected corona patients, and those infected but not requiring hospitalization, at home while still providing them with optimal care.

Hospitals and HMOs will be able to quickly deploy a robust and scalable COVID-19 telemedicine solution tailored to provide virtual services, including online symptom-checking tools and remote consultations with doctors, while simultaneously minimizing direct contact with those infected with the coronavirus.

The Datos COVID-19-specific telemedicine package is already in use at Sheba Medical Center, Israel’s largest hospital, and has begun implementations in U.S. hospital systems.

“Datos is providing an important solution for the US health care system to monitor COVID-19 remotely, easing the demand for inpatient-based monitoring at hospitals,” said Uri Bettesh, CEO of Datos Health. “The first solution of its kind, we are able to deploy it within 48 hours. It requires no additional resources as it seamlessly integrates with care teams’ existing workflows, providing crucial insights into patients being monitored outside the hospital at a fraction of the cost. Treating patients – who do not require hospitalization – out of emergency rooms could ensure that key resources are available for the most serious cases.”

The Datos COVID-19 solution offers:

  • For care teams, a fully configured COVID-19 dashboard that includes an overall view of all patients sorted according to the severity of coronavirus symptoms, the delivery of daily symptom checkout surveys, the seamless launch of virtual visits via video calls (including via text message, without requiring the Datos app), data-driven reminders (to measure temperature and complete surveys), messages and content.
  • For patients, a user-friendly mobile app (available on iOS and Android) for home hospitalized patients to manually enter their relevant vitals, including body temperature, BP and saturation. Patients will be asked to respond to two types of coronavirus surveys, an initial assessment followed by daily symptom status updates, sent automatically and then scored and correlated with monitored vitals to yield timely reminders, personalized messages and virtual doctor visits via video calls.

The solution additionally provides health systems with a private, HIPAA compliant, cloud-based interface of the Datos platform anywhere in the world. Optional extras include services delivered via a text message with links to web pages for reporting vitals management, survey distribution and video calls.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy